Diagnostic Methods for the Prediction of Therapeutic Success, Recurrence Free and Overall Survival in Cancer Therapy

• US 20090298061A1
• Filed: 07/20/2006
• Published: 12/03/2009
• Est. Priority Date: 07/29/2005
• Status: Abandoned Application

• Current Assignee: Siemens Healthcare Diagnostics Incorporated (Siemens AG)
• Original Assignee: Siemens Healthcare Diagnostics Incorporated (Siemens AG)
• Inventors: Wirtz, Ralph Markus
• Application Number:
  US11/989,830
• Publication Number:
  US 20090298061A1
• Time in Patent Office: Days
• US Class Current: 435/6.16
• CPC Class Codes: C12N 15/1136 against growth factors, growth regulators, cytokines, lymphokines or hormones
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/106 Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
• CPC Class Codes: C12Q 2600/118 Prognosis of disease development
• CPC Class Codes: C12Q 2600/136 Screening for pharmacological compounds

Abstract

Described are 12 human genes which are differentially expressed in neoplastic tissues of patients responding well to treatment as compared to patients not responding well as determined by overall survival time in the non responding cohort. Moreover, methods for prognosis of the therapeutic success in cancer therapy are described. These methods are based on determination of expression levels of particular genes which are differentially expressed in cancer patients, preferably the genes encoding VEGFC, ERBB3 and Her2/neu, prior to the onset of anti-cancer chemotherapy. These methods are particularly useful in the investigation of advanced head and neck cancer, but are useful in the investigation of other types of cancer and therapies as well.

Claims

1. A method for predicting therapeutic success of a given mode of treatment in a patient having cancer or for adapting therapeutic regimen based on individualized risk assessment for a patient having cancer, comprising

(a) obtaining a biological sample from said patient;

(b) determining the pattern of expression levels of at least one marker gene of the group of marker genes listed in Table 1;

(c) comparing the pattern of expression levels determined in (b) with one or several reference pattern(s) of expression levels; and

(d) predicting therapeutic success for said given mode of treatment in said subject or implementing therapeutic regimen targeting said marker genes in said subject from the outcome of the comparison in step (c).

2. The method of claim 1, wherein in step (b) the pattern of expression levels of at least three marker genes is determined.

3. The method of claim 2, wherein in step (b) the pattern of expression levels of at least six marker genes is determined.

4. The method of claim 1, comprising

(a) obtaining a biological sample from a patient;

(b) determining at least the pattern of expression levels of VEGFC, ERBB3 and/or Her2/neu;

(c) comparing the pattern of expression levels determined in (b) with one or several reference pattern(s) of expression levels;

wherein (i) upregulated expression of VEGFC and/or (ii) downregulated expression of ERBB3 and/or Her2/neu is indicative of a poor prognosis as regards therapeutic success for said given mode of treatment in said subject.

5. The method of claim 1, wherein said given mode of treatment (a) acts on recruitment of lymphatic vessels, cell proliferation, cell survival and/or cell motility, and/or (b) comprises administration of a chemotherapeutic agent.

6. The method of claim 5, wherein said given mode of treatment comprises chemotherapy, administration of small molecule inhibitors, antibody based regimen, anti-proliferation regimen, pro-apoptotic regimen, pro-differentiation regimen, radiation and/or surgical therapy.

7. A method of selecting a therapy modality for a patient afflicted with a neoplastic disease, comprising

(a) obtaining a biological sample from said patient;

(b) predicting from said sample, by the method of any one of claims 1 to 6, therapeutic success for a plurality of individual modes of treatment; and

(c) selecting a mode of treatment which is predicted to be successful in step (b).

8. The method of claim 7, comprising

(a) obtaining a sample comprising cancer cells from said patient;

(b) separately maintaining aliquots of the sample in the presence of one or more test compositions;

(c) comparing expression of a single or plurality of marker genes, selected from the marker genes listed in Table 1 in each of the aliquots; and

(d) selecting a test composition which induces a lower level of expression of genes from Table 1 and/or a higher level of expression of genes from Table 1 in the aliquot containing that test composition, relative to the level of expression of each marker gene in the aliquots containing the other test compositions.

9. The method of claim 1, wherein the expression level is determined by

(a) a hybridization based method;

(b) real time real time PCR;

or

(c) determining the protein level.

10. The method of claim 9, wherein said hybridization based method utilizes arrayed probes or individually labeled probes.

11. The method of claim 1, wherein said cancer or neoplastic disease is HNSCC, breast or colon cancer.

15. The method of claim 1, wherein in step (b) the pattern of expression levels of at one marker genes is determined.

16. The method of claim 1, wherein in step (b) the expression levels of VEGFC is determined.

17. The method of claim 1, wherein in step (b) the expression levels of ERBB2 is determined.

18. The method of claim 1, wherein in step (b) the expression levels of ERBB3 is determined.

12. A kit useful for carrying out a method for predicting therapeutic success of a given mode of treatment in a patient having cancer or for adapting therapeutic regimen based on individualized risk assessment for a patient having cancer, comprising at least (a₁) three primer pairs and/or (a₂) three probes each having a sequence sufficiently complementary to the gene encoding VEGFC, ERBB3 and/or Her2/neu and/or (b) at least three antibodies directed against VEGFC, ERBB3 and Her2/neu.

13. A method for the treatment of a cancer associated with the recruitment of lymphatic vessels by expression of VEGFC comprising administering an effective amount of (a) an anti-VEGFC antibody, (b) an antisense nucleic acid or a ribozyme inhibiting the expression of the VEGFC encoding gene or (c) an inactive version of VEGFC as an antagonist.

14. The method according to claim 13, wherein said cancer is HNSCC, breast or colon cancer.